Mankind Pharma's Q4 FY 2025-26 Quarterly Results

Result Summary

• Mankind Pharma Ltd reported a 2.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 6.8%.
• Its expenses for the quarter were down by 4.9% QoQ and up 2.1% YoY.
• The net profit increased 35.2% QoQ and increased 31.7% YoY.
• The earnings per share (EPS) of Mankind Pharma Ltd stood at 13.41 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Mankind Pharma Ltd is a leading pharmaceutical company based in India. The company is known for manufacturing and marketing a wide range of pharmaceutical products, including over-the-counter medicines, prescription drugs, and a variety of other healthcare products. Mankind Pharma operates in the pharmaceutical industry, which is characterized by high levels of research and development, regulatory oversight, and market competition. While specific recent developments regarding Mankind Pharma are not available, the company is generally recognized for its extensive product portfolio and strong distribution network across India and other regions.

Revenue

In the fourth quarter of fiscal year 2026 (Q4FY26), Mankind Pharma Ltd reported a total income of ₹3557.22 crores. This represents a slight quarter-over-quarter decrease of 2.3% compared to the previous quarter (Q3FY26), where the total income was ₹3639.95 crores. On a year-over-year basis, total income increased by 6.8% from ₹3330.70 crores in Q4FY25. This growth in total income over the year indicates a positive trend, reflecting the company's ability to generate higher revenues compared to the same period in the previous year.

Profitability

Mankind Pharma Ltd's profitability showed significant improvement in Q4FY26. The company recorded a profit before tax of ₹656.18 crores, which is a 29.7% increase from the ₹505.79 crores reported in Q3FY26. Year-over-year, profit before tax rose by 27.9% from ₹513.11 crores in Q4FY25. The tax expense for Q4FY26 was ₹99.75 crores, marginally increasing by 4.9% from ₹95.12 crores in the previous quarter and by 15.4% from ₹86.44 crores in Q4FY25. Consequently, profit after tax for the quarter was ₹559.42 crores, marking a significant 35.2% increase from the previous quarter's ₹413.88 crores and a 31.7% rise from ₹424.65 crores in Q4FY25. Earnings per share for Q4FY26 were ₹13.41, up from ₹9.89 in Q3FY26 and ₹10.18 in Q4FY25, reflecting the overall improvement in profitability.

Operating Metrics

In the fourth quarter of fiscal year 2026, Mankind Pharma Ltd's total expenses amounted to ₹2877.88 crores, which is a 4.9% reduction from the ₹3027.57 crores recorded in the third quarter of the same fiscal year. On a year-over-year basis, total expenses increased slightly by 2.1% from ₹2817.59 crores in Q4FY25. This indicates a controlled increase in expenses relative to the growth in total income. The reduction in expenses compared to the previous quarter contributed positively to the improvement in profitability for Q4FY26. The company's ability to manage its expenses effectively is an important aspect of its operational efficiency, as reflected in the financial data.